Commentary

Podcast

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at the importance of telehealth during policy uncertainty, the growing popularity of Medicare Advantage special needs plans, and Halozyme’s latest acquisition.

  • The American Telemedicine Association is warning that the US must preserve telehealth access to avoid setbacks in healthcare delivery during the federal government shutdown. Advocates argue that telehealth has become an essential lifeline for patients, particularly in rural and underserved communities. Without clear policies, they say millions could face disruptions in care, highlighting the urgent need for permanent telehealth protections.
  • A new report from KFF shows that Medicare Advantage special needs plans, or SNPs, are becoming increasingly popular among seniors. Enrollment has more than doubled over the past five years, reflecting demand for tailored coverage options for patients with chronic conditions or complex health needs. Experts note that while SNPs can improve care coordination, they also require careful oversight to ensure quality and equity across different populations.
  • Lastly, in business news, Halozyme has signed a $750 million definitive agreement to acquire Elektrofi, a biotechnology company specializing in ultra-concentrated drug formulations. The deal is expected to expand Halozyme’s drug delivery capabilities and strengthen its partnerships with major pharma companies. Industry analysts say the acquisition could accelerate development of next-generation therapies and broaden Halozyme’s role in biopharma innovation.

From protecting telehealth access and evolving Medicare coverage to major biopharma acquisitions, these stories illustrate the interplay of policy, patient needs, and industry strategy shaping healthcare today.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on AudioboomSpotify, or iHeart.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.